Voluntary announcement regarding the completion of transactions with GSK ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (“Aspen Holdings”) Registration number: 1985/0002935/06 Share code: APN ISIN: ZAE000066692 and its subsidiaries (collectively “Aspen” or “the Group”) VOLUNTARY ANNOUNCEMENT REGARDING THE COMPLETION OF TRANSACTIONS WITH GSK IN RESPECT OF: 1. THE EXERCISE OF AN OPTION TO ACQUIRE FRAXIPARINE AND ARIXTRA IN COUNTRIES RETAINED BY GSK; AND 2. THE CANCELLATION OF ASPEN’S COLLABORATION WITH GSK IN SUB-SAHARAN AFRICA Shareholders are referred to the announcement released by Aspen Holdings on 12 September 2016 wherein it was, inter alia, confirmed that: 1. Aspen Global Incorporated (“AGI”) had exercised its option to acquire Fraxiparine and Arixtra in certain countries to which GSK retained the rights, most notably China, for a consideration of £45 million; and 2. Pharmacare Limited (“Pharmacare”) and GSK had agreed to cancel the rights of Pharmacare to collaborate in the sub-Saharan business of GSK (“the SSA Collaboration”) and that GSK would pay Pharmacare £45 million as consideration for the cancellation of the SSA Collaboration. Aspen Holdings is pleased to announce that these transactions completed on 31 December 2016. Durban 3 January 2017 Sponsor: Investec Bank Limited About Aspen Aspen is a leading global player in specialty, branded and generic pharmaceuticals with an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. Aspen continues to increase the number of lives benefitting from its products, reaching more than 150 countries. Aspen has a strong presence in both emerging and developed countries. Its emerging market footprint includes Sub-Saharan Africa, Latin America, South East Asia, Eastern Europe and the Commonwealth of Independent States, comprising Russia and the former Soviet Republics. From a developed world perspective Aspen is one of the leading pharmaceutical companies in Australia and has a growing presence in other developed countries, most notably in Western Europe. Aspen operates with an established business presence in approximately 50 countries spanning 6 continents and employs more than 10,000 people. The Group operates 26 manufacturing facilities across 18 sites. Aspen holds international manufacturing approvals from some of the most stringent global regulatory agencies including the FDA, TGA and EMA. Aspen’s manufacturing capabilities are scalable to demand and cover a wide variety of product-types including oral solid dose, liquids, semi-solids, steriles, biologicals, APIs and infant nutritionals. Aspen, with a market capitalisation of approximately $10 billion, is the largest pharmaceutical company listed on the JSE Limited (share code: APN) and ranks amongst the top 20 listed companies on this exchange. For more information visit: http://www.aspenpharma.com/ Date: 03/01/2017 09:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.